Congressional Research Service Reports - 537 Matching Results

Search Results

Prescription Drug User Fee Act of 1992: Effects on Bringing New Drugs to Market
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
No Description Available.
Medicare's Skilled Nursing Facility Benefit
No Description Available.
Tobacco Price Support: An Overview of the Program
No Description Available.
Genetic Exceptionalism: Genetic Information and Public Policy
This report provides an overview of the nature of genetic information and its implications for individuals, family, and society. Individuals utilize genetic information to guide health care and other decisions, when possible, and may experience anxiety as a result of genetic test results. Genetic test results for an individual may often be informative for other close family members and thus influence their care decisions. Society must grapple with the effect genetic information may have on our conception of disease, as well as its impact on issues like privacy and equity. The report ends by summarizing the main policy issues involved with a genetic exceptionalist approach to public policy, including defining genetic information; physically separating genetic information from other medical information; unintended disparities between “genetic” and “nongenetic” disease; and the effect of legislation on participation in genetic research, on uptake of genetic technology and on the delivery of high quality health care.
Stem Cell Research
No Description Available.
Stem Cell Research
No Description Available.
Stem Cell Research
No Description Available.
Stem Cell Research
No Description Available.
Stem Cell Research
No Description Available.
Prescription Drugs: Importation for Personal Use
No Description Available.
Stem Cell Research
No Description Available.
Stem Cell Research
No Description Available.
Stem Cell Research
No Description Available.
Stem Cell Research
No Description Available.
Importing Prescription Drugs
No Description Available.
Importing Prescription Drugs
No Description Available.
Importing Prescription Drugs: Objectives, Options, and Outlook
No Description Available.
Labeling of Genetically Modified Foods
No Description Available.
Medical Malpractice Liability Reform: Legal Issues and Fifty-State Survey of Caps on Punitive Damages and Noneconomic Damages
No Description Available.
Medical Malpractice Liability Reform: Legal Issues and Fifty-State Survey of Caps on Punitive Damages and Noneconomic Damages
No Description Available.
Medical Malpractice Liability Reform: Legal Issues and Fifty-State Survey of Caps on Punitive Damages and Noneconomic Damages
No Description Available.
Medical Malpractice Liability Reform: Legal Issues and Fifty-State Survey of Caps on Punitive Damages and Noneconomic Damages
No Description Available.
Medical Malpractice Liability Reform: Legal Issues and Fifty-State Survey of Caps on Punitive Damages and Noneconomic Damages
No Description Available.
Medical Malpractice Liability Reform: Legal Issues and Fifty-State Survey of Caps on Punitive Damages and Noneconomic Damages
No Description Available.
Medical Malpractice Liability Reform: Legal Issues and Fifty-State Survey of Caps on Punitive Damages and Noneconomic Damages
No Description Available.
Medical Malpractice Liability Reform: Legal Issues and Fifty-State Survey of Caps on Punitive Damages and Noneconomic Damages
No Description Available.
Medical Malpractice Liability Reform: Legal Issues and Fifty-State Survey of Caps on Punitive Damages and Noneconomic Damages
No Description Available.
Vaccine Policy Issues
No Description Available.
Veterans' Benefits Issues in the 109th Congress
No Description Available.
Veterans' Medical Care Appropriations and Funding Process
No Description Available.
Veterans' Medical Care: FY2006 Appropriations
No Description Available.
Veterans' Medical Care: FY2006 Appropriations
No Description Available.
Background and Legal Issues Related to Stem Cell Research
In August 2001, President Bush announced that federal funds, with certain restrictions, may be used to conduct research on human embryonic stem cells. This report explains the limitations on this research, as well as corresponding and related legislation to the issue of embryonic stem cell research, including the Stem Cell Research Enhancement Act of 2005.
Background and Legal Issues Related to Stem Cell Research
In August 2001, President Bush announced that federal funds, with certain restrictions, may be used to conduct research on human embryonic stem cells. Federal research is limited to “the more than 60” existing stem cell lines that were derived (1) with the informed consent of the donors; (2) from excess embryos created solely for reproductive purposes; and (3) without any financial inducements to the donors. No federal funds may be used for the derivation or use of stem cell lines derived from newly destroyed embryos; the creation of any human embryos for research purposes; or cloning of human embryos for any purposes.
Food Labeling: Allergy Information
Media attention to food allergies is the result of the recent tracking of food allergy sufferers and a clear rise in the number of affected individuals. Several efforts are underway to improve the ability of individuals who have a food allergy to avoid products that cause symptoms that can range from mild to serious. The Food and Drug Administration (FDA) and the Food Allergy Issues Alliance each have released guidelines to address the issues of labeling and cross-contamination. Nine state attorneys general have petitioned FDA for stricter rules, which are also supported by some consumer groups. The FY2002 agriculture appropriations bill directed FDA to address and report on cross-contamination; however, this report had not yet been submitted. Most recently, the Food Allergen Labeling and Consumer Protection Act of 2004 (P.L. 108-282) was enacted on August 2, 2004. This report will provide background on food allergies and review efforts to provide improved labeling information for food allergy sufferers; it will be updated to reflect legislative or other activity.
Influenza Vaccine Shortages and Implications
No Description Available.
Labeling of Genetically Modified Foods
No Description Available.
Influenza Antiviral Drugs and Patent Law Issues
This report examines the role that intellectual property rights play in affecting the availability of a patented drug such as Tamiflu during public health crises. The report also explains one legal mechanism for increasing a patented drug’s production without the patent holder’s consent: governments may abrogate a pharmaceutical company’s patent rights by issuing compulsory licenses to other drug companies to manufacture generic versions of the drug.
Pandemic Influenza: Domestic Preparedness Efforts
No Description Available.
DNA Testing for Law Enforcement: Legislative Issues for Congress
DNA evidence is a powerful forensic tool in criminal cases. Its use and capabilities have increased substantially since it was first introduced in the late 1980s. That growth has led to the emergence of the following issues that were considered by the 106th Congress in legislative initiatives: eliminating the nationwide backlog of unanalyzed DNA samples, expanding the kinds of offenders who are profiled, providing opportunities for post-conviction testing of DNA evidence, and continuing development of forensic science capabilities. This report discusses those and related issues and the legislation proposed and enacted to address them. It begins by describing provisions in prior federal law and then discusses issues and the legislation proposed, including the enacted DNA Analysis Backlog Elimination Act of 2000 (H.R. 4640, which became P.L. 106-546).